US appeals court reverses $1.67 BN decision against Abbott in Humira patent case
This article was originally published in Scrip
Executive Summary
A federal appeals court has overturned a two-year-old jury verdict that found that Abbott Laboratories, maker of the arthritis drug and mAb against TNF alpha, Humira (adalimumab), had to pay $1.67 billion in damages to Johnson & Johnson's Centocor subsidiary for wilful infringement of a patent held by Centocor covering anti-TNF technology.